Category: Lymphoma
DA-R-EPOCH vs R-CHOP in DLBCL: How Do We Choose?
Abstract: The emerging molecular and prognostic characterization of diffuse large B-cell lymphoma (DLBCL) has challenged the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treatment paradigm in […]
Evolving Strategies for the Management of Transformed Lymphoma
H&O What is transformed lymphoma? SS Transformed lymphoma refers to a more aggressive or fast-growing lymphoma that arises from an indolent histology. The most common example […]
How We Treat Mycosis Fungoides and Sézary Syndrome
Overview • Mycosis fungoides/Sézary syndrome is managed as a chronic disease. • Skin-directed therapy is most effective for early-stage disease. • Sequential single-agent therapy is more […]
Are Novel Agents Ready to Assume the Mantle in the Frontline Treatment of Mantle Cell Lymphoma?
Abstract: Although chemotherapy has been a mainstay of the frontline treatment of mantle cell lymphoma (MCL) for many years, novel agents—including Bruton kinase inhibitors, immunomodulatory agents, […]
Lenalidomide in DLBCL: Are We Past the Cell of Origin?
Abstract: Single-agent lenalidomide has modest activity in diffuse large B-cell lymphoma (DLBCL) and is thought to be more potent in activated B-cell (ABC) lymphomas, which are […]
Recently Approved Drugs Herald a New Era in Therapy for Diffuse Large B-Cell Lymphoma
H&O What are the standard treatments for diffuse large B-cell lymphoma (DLBCL)? GN For nearly 20 years, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has […]
A Closer Look at Tazemetostat
Tazemetostat (Tazverik, Epizyme) is an oral EZH2 inhibitor. In June 2020, the US Food and Drug Administration (FDA) granted accelerated approval to tazemetostat for the […]
Duvelisib, a New PI3K Inhibitor for Lymphoid Malignancies
H&O What type of drug is duvelisib? NL Duvelisib (Copiktra, Verastem Oncology) is an orally bioavailable, highly selective and potent small-molecule inhibitor of the delta […]
Optimizing the Use of Oral Therapy in Lymphoma
H&O Approximately what percentage of treatments for lymphoma are now administered orally? JF Administration of oral therapy in lymphoma is a rapidly evolving area. Frequency […]
How Disease Stage Impacts the Rate of Second Primary Malignancies in Patients With Diffuse Large B-Cell Lymphoma
H&O How common are second primary malignancies among patients with diffuse large B-cell lymphoma (DLBCL)? MK Nearly 60% of patients with DLBCL can be cured […]
Emerging Therapeutic Targets in Follicular Lymphoma
H&O What is the objective of the Wendel Laboratory? HGW We are interested in understanding the genetic and biologic mechanisms that lead to cancer in […]
Prophylaxis of Central Nervous System Relapse in Patients With Lymphoma
H&O How common is central nervous system relapse in lymphoma? AK The incidence of central nervous system (CNS) relapse in lymphoma depends on the type […]
Measurement of Circulating Tumor DNA to Guide Management of Patients with Lymphoma
Abstract In recent years, advances have been made in methods to assess response to therapy in lymphoma. Ideally, response assessment tools should be highly sensitive […]
Surveillance Scanning in Lymphoma
Abstract: Although the role of imaging in the management of most lymphomas is well established at baseline, during treatment, and following treatment, surveillance imaging after […]
Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma: Review of Current Evidence and Future Directions
Abstract: Mantle cell lymphoma (MCL) is a heterogeneous and uncommon non-Hodgkin lymphoma that affects predominantly older patients and often is associated with an aggressive clinical […]
A New Target in CTCL: Treating the Skin, Blood, and Lymph Nodes
H&O What are the main subtypes of cutaneous T-cell lymphoma? SH Cutaneous T-cell lymphoma (CTCL) refers to a group of non-Hodgkin lymphomas that present primarily or […]
Management of Adults With Burkitt Lymphoma
Abstract: Burkitt lymphoma (BL) is a highly aggressive B-cell non-Hodgkin lymphoma characterized by marked tumor proliferation resulting from translocation of the MYC oncogene. Distinct clinical […]
Loncastuximab Tesirine in Patients With B-Cell Non-Hodgkin Lymphoma
H&O What type of drug is loncastuximab tesirine? BK Loncastuximab tesirine is a novel antibody-drug conjugate. Antibody-drug conjugates consist of 3 components: a monoclonal antibody, […]
Cellular Immunotherapy for Non-Hodgkin Lymphoma
H&O What types of cellular immunotherapy are being investigated in non-Hodgkin lymphoma? CB It is important to distinguish between the types of cellular immunotherapy available […]
The Use of Chimeric Antigen Receptor T Cells in Patients With Non-Hodgkin Lymphoma
Abstract: Resistance to conventional lines of therapy develops in approximately 20% of all patients with lymphoma. These patients have a dismal prognosis, with an expected […]